脂肪瘤与皮下脂肪细胞药理学特性差异的研究  

A study on the pharmacological characteristic diversities between human lipomatous cells and subcutaneous fat cells

作　　者：卢盛华[1] 曹伟[1] 马剑峰[1] 王菊英[1] 刘萍[1] 

机构地区：[1]山东医科大学基础医学院药理学教研室

出　　处：《中国药理学通报》1998年第2期175-177,共3页Chinese Pharmacological Bulletin

基　　金：山东省自然科学基金

摘　　要：目的研究脂肪瘤细胞与皮下脂肪细胞药理学特性的差异，为探讨脂肪瘤的形成机制和非手术治疗的方法提供理论依据。方法用不同浓度的异丙肾上腺素、肾上腺素、去甲肾上腺素和ＢＲＬ３７３４４分别激动离体人脂肪瘤和皮下脂肪细胞上的β受体，根据β受体激动后产生的ｃＡＭＰ的量效曲线和最大效应，分析脂肪瘤细胞和皮下脂肪细胞上β受体药理学特性的差异。结果几种不同的β受体激动剂脂肪瘤细胞上的β受体后产生ｃＡＭＰ的最大效应均小于正常皮下脂肪细胞。几种激动剂激动２种脂肪细胞上的β受体作用强度顺序相同，即异丙肾上腺素＞肾上腺素＞去甲肾上腺素＞ＢＲＬ３７３４４。ＢＲＬ３７３４４对２种脂肪细胞上β受体的激动作用都很微弱，且最大效应间无显著差异。结论脂肪瘤细胞上的β肾上腺素受体对β受体激动剂的敏感性低于正常皮下脂肪细胞。ＢＲＬ３７３４４对人脂肪瘤细胞和皮下脂肪细胞上β受体的激动作用微弱。AIM To provide theoretical evidence for mechanism of lipomata formation and method of its nonoperation treatment, through the study of the diversities of pharmacological characteristics between lipomatous cells and normal subcutanous fat cells. METHODS We used isoprenaline, adrenaline, noradrenaline and BRL 37344 to activate the β adrenoreceptors on isolated human lipoma and subcutaneous fat cells respectively. On the basis of doseeffect curve of producted cAMP after β adrenoreceptors were activated, we analysed the diversities of pharmacological characteristics of β adrenoreceptors on the membrane of lipomtous cells and subcutaneous fat cells. RESULTS The potency orders of those different agonists for the two kinds of fat cells were identical, isoprenaline > adrenaline > noradrenaline > BRL 37344. But the maximal effect of producting cAMP of those agonists in lipomatous fat cells were smaller than that of those agonist in subcutaneous fat cells. In addition, BRL 37344 had a weak effect on both kinds of fat cells and the maximal effects of both were not distinct. CONCLUSION The sensitivity of β adrenoreceptors on lipomatous cells to adrenoreceptors agonists is lower than that of on subcutaneous. The BRL 37344 has only a little effect in activiting β adrenoreceptors on both kinds of fat cells.

关 键 词：脂肪瘤 皮下脂肪细胞 药理学 特性差异 BAR 

分 类 号：R730.262[医药卫生—肿瘤] R966[医药卫生—临床医学]